TapImmune improves T-cell vaccine formulation ahead of Ph II trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: TapImmune)
(Image: TapImmune)

Related tags: Clinical trial

TapImmune has completed a multi-gram scale-up and GMP manufacturing of its lead product as it prepares for various Phase II studies.

TapImmune is a clinical-stage immune-oncology company that specializes in developing gene-based immunotherapeutics and vaccines for treating cancer and other diseases. The company’s current lead product, TPIV 200, is a multi-epitope T-cell vaccine targeting folate receptor alpha.

The first TPIV 200 lot was manufactured in early 2016, since which time the company has made improvements to the manufacturing process in order improve scalability.

Dr. Glynn Wilson, Chairman and CEO of TapImmune told us that the basic improvement was in yield and a product that is more amenable to commercialization.

The formulation change also improves the physical appearance and consistency of the final vialed product.

Phase II trials

The second clinical lot of TPIV 200 will support a planned Phase II trial sponsored by Mayo Clinic, which will evaluate the vaccine for the treatment of triple-negative breast cancer.

The batch will also support a separate, ongoing Phase II trial in patients with platinum-resistant ovarian cancer. The TapImmune-sponsored trial will evaluate the vaccine in combination with a checkpoint inhibitor and is currently enrolling patients.

Immunotherapy is the hottest space in oncology right now​,” explained Wilson, adding that the success of checkpoint inhibitors, such as Opdivo have shown significant promise.

But in the future these are going to have to be used in combination with other agents, such as T-cell vaccines, in order to improve the overall response rate​.” 

Related news

Show more

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 21-May-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more